Table 2.
Characteristics | Control group (n = 63) | Genotype‐guided group (n = 62) |
---|---|---|
Age, mean ± SD (y) | 36.41 ± 13.27 | 39.56 ± 14.05 |
Male sex, n (%) | 50 (79.4) | 48 (77.4) |
Body mass index, mean ± SD (kg/m 2 ) | 23.44 ± 3.47 | 23.31 ± 2.78 |
Causes of brain death, n (%) | ||
Trauma related events | 46 (73.0) | 42 (67.7) |
Nontrauma related events | 17 (27.0) | 20 (32.3) |
Marginal donor, n (%) | 12 (19.1) | 16 (25.8) |
Duration of admission, mean ± SD (h) | 60.45 ± 43.74 | 64.18 ± 56.95 |
Duration of shock, mean ± SD (h) | 6.85 ± 7.33 | 5.35 ± 6.66 |
Duration of oliguria, mean ± SD (h) | 1.68 ± 4.09 | 1.27 ± 4.76 |
Duration of norepinephrine administration, mean ± SD (h) | 15.10 ± 17.47 | 15.99 ± 17.90 |
Duration of dopamine administration, mean ± SD (h) | 21.25 ± 22.55 | 18.40 ± 20.26 |
Serum creatinine before harvest, mean ± SD (mg/dL) | 1.28 ± 0.70 | 1.26 ± 0.66 |
Present of arrest, n (%) | 4 (6.3) | 2 (3.2) |
Level of urine albumin before harvest, % | ||
0/trace/1+/2+/3+ | 62.3/11.5/21.3/4.9/0 | 57.6/18.6/17.0/5.1/1.7 |
Urine red blood cells, mean ± SD (cells/hpf) | 8.75 ± 17.47 | 13.85 ± 18.66 |
Urine white blood cells, mean ± SD (cells/hpf) | 3.21 ± 3.86 | 4.00 ± 5.00 |
hpf, high‐power field; SD; standard deviation.